#Japan #Tokyo #AbbVie #RINVOQ #Juvenile Arthritis

AbbVie Launches RINVOQ in Japan

AbbVie, a leading pharmaceutical company headquartered in Tokyo, has announced the launch of its new medication, RINVOQ (upadacitinib), in Japan as of October 23, 2026. This innovative treatment targets polyarticular juvenile idiopathic arthritis (pcJIA), a severe autoimmune condition affecting children. RINVOQ is a Janus kinase (JAK) inhibitor that was given the green light for use in patients aged two and older who have inadequately responded to existing therapies.

What is Juvenile Idiopathic Arthritis?

Juvenile idiopathic arthritis (JIA) is a chronic, inflammatory autoimmune disease that affects children, typically before the age of 16. It manifests as unexplained arthritis lasting for more than six weeks. According to the International League of Associations for Rheumatology (ILAR), JIA is classified into seven subtypes, with pcJIA being defined as arthritis affecting five or more joints during the disease course. Approximately 30% of JIA cases fall under the pcJIA classification, marking it as a significant concern.

Symptoms of pcJIA often include limping, morning stiffness, decreased activity levels, swollen joints, and difficulties with fine motor skills. Alarmingly, more than 45% of those diagnosed with pcJIA are likely to experience persistent disease activity into adulthood, which can significantly detract from their quality of life due to long-term functional limitations.

Details of RINVOQ

RINVOQ is administered orally with varying dosages based on patient weight. The specifics are as follows:

• - For patients weighing between 10 kg and less than 20 kg: 3 mL (3 mg) twice daily.
• - For patients weighing between 20 kg and less than 30 kg: 4 mL (4 mg) twice daily.
• - For patients weighing 30 kg or more: 15 mg once daily or 6 mL (6 mg) twice daily.

This drug has undergone rigorous testing and approval processes, with its manufacturing and sales approvals secured recently. Notably, its effectiveness has been previously established in treating other conditions such as rheumatoid arthritis, ankylosing spondylitis, and ulcerative colitis.

AbbVie’s Commitment to Immunology

AbbVie has always been at the forefront of developing solutions for autoimmune diseases. With over two decades of expertise and commitment, they strive to enhance standard treatment options for those living with immunological conditions. Currently, more than one million patients around the world benefit from AbbVie’s immunology portfolio, which addresses over twenty different immune-mediated diseases.

The company's mission extends to unlocking advancements in treatment through innovative sciences and reliable medications, and they emphasize the importance of broadening access to effective therapies.

Future Developments

Looking ahead, AbbVie aims to continue expanding its research and development efforts in the immunology sector. By investing in groundbreaking modalities and novel pathways, the company seeks to tackle complex autoimmune disorders, ensuring that patients receive meaningful advancements in care.

For more detailed information on RINVOQ, and to learn more about AbbVie’s endeavors in immunology, interested parties are encouraged to visit AbbVie’s website.

Conclusion

The introduction of RINVOQ represents a critical step forward for the treatment of polyarticular juvenile idiopathic arthritis in Japan. With this launch, AbbVie aims to address the unmet needs of patients and improve their overall quality of life, solidifying its role as a leader in immunology.